Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02605785 · ClinicalTrials.gov registry record · NA

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

A NA study of Progressive Supranuclear Palsy, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
332
Enrollment target
1
Study location

NCT02605785 is a NA study of Progressive Supranuclear Palsy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 332 participants, below the 434-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02605785, a NA study of Progressive Supranuclear Palsy, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
332 participants
Enrollment target
1
Study location

Study Summary

This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).

Interventions

  • DRUG F-18 AV 1451

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 332 participants
Start Date 2015-11
Est. Completion 2030-01
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT02605785

The ClinicalTrials.gov registry entry for NCT02605785 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 434-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (24% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 1 intervention - of which F-18 AV 1451 is the first listed.

NCT02605785 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02605785 about?

NCT02605785 is a clinical study titled "A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy". This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).

What is the current status of trial NCT02605785?

This trial is currently recruiting. It is a NA study. The enrollment target is 332 participants. The study started on 2015-11. Estimated completion is 2030-01.

What conditions does trial NCT02605785 study?

This clinical trial studies the following conditions: Progressive Supranuclear Palsy.

What interventions are being tested in trial NCT02605785?

The interventions under investigation include: F-18 AV 1451 (DRUG).

Who is sponsoring clinical trial NCT02605785?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02605785 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Progressive Supranuclear Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.